로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Cell > HVEM > CHEK-ATF105

Human HVEM (Luc) HEK293 Reporter Cell

Order Now

  1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
  2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
  3. Comprehensive application data to support assay development and validation
  4. Full tracible record, stringent quality control and validated cell passage stability
  5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
  6. Global commercial license assistance whenever regulatory filing is required
  • Description
    The Human HVEM (Luc) HEK293 Reporter Cell was engineered to not only express NF-kB signaling response element, but also express the receptor full length human HVEM (Uniprot: Q92956-1). When co-cultured with target cells expressing human BTLA, the BTLA/HVEM interaction drives NF-kB-mediated luminescence. Blocking the BTLA/HVEM interaction by either anti-BTLA or anti-HVEM antibodies results in a decrease in luminescence.
  • Application

    • Screen for anti-human BTLA antibody or anti-human HVEM antibody blocking BTLA/HVEM interaction.

     HVEM Assay Principles

  • Growth Properties
    Adherent
  • Selection Marker
    Hygromycin B (20 μg/mL)
  • Complete Growth Medium
    DMEM medium + 10% FBS
  • Freeze Medium
    Serum-free cell cryopreservation medium
  • Quantity
    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
  • Storage
    Frozen in liquid nitrogen.
  • Mycoplasma Testing
    Negative
  • Sterility Testing
    Negative
  • Instructions for Use
    See data sheet for detailed culturing and assay protocol.

Receptor Assay
 HVEM FACS

Expression analysis of human HVEM on Human HVEM (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on Human HVEM (Luc) HEK293 Reporter Cell or negative control cell using
PE-labeled anti-human HVEM antibody

Application
 HVEM APPLICATION

Inhibition of human BTLA overexpressing on CHO cells induced reporter activity by anti-human BTLA antibody.
This reporter cell was incubated with serial dilutions of antibodies in the presence of CHO/Human BTLA Stable Cell Line (Cat. No. SCCHO-ATP110). The EC50 of anti-human BTLA neutralizing antibody is approximately 0.212 μg/mL.

Signaling Bioassay
 HVEM SIGNALING

Response to human BTLA (FOLD).
This reporter cell was incubated with CHO/Human BTLA Stable Cell Line (Cat. No. SCCHO-ATP110) at four different cell densities. The human BTLA overexpressing on CHO cells can activate HVEM signaling with the max induction fold 103.69 at the density of 8x10^4 cells/well.

Passage Stability
 HVEM PASSAGE

Passage stability analysis by Signaling Bioassay.
The continuously growing Human HVEM (Luc) HEK293 Reporter Cell was incubated with CHO/Human BTLA Stable Cell Line (Cat. No. SCCHO-ATP110). The human BTLA overexpressing on CHO cells stimulated response demonstrates passage stabilization (fold induction) across passage 7-25.

Please contact us if you are interested in related cell pool service.

  • Limited Use&License Disclosure

    BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.

    1. If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
    2. Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
    3. This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use . You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
    4. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
    5. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
    6. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order@acrobiosystems.com for further details.
  • Clinical and Translational Updates

Comments (0)


ETA of in-stock products: 2 business days

Price(USD) : $13150.00

Drug Candidate Licensing

more

Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:0 Details
  • Latest Research Phase:Preclinical

Datasheet & Documentation

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop